Direct detection of early-stage cancers using circulating tumor DNA.

Science translational medicine (2017 Aug)
Issue 403 issn:1946-6242)

Early detection and intervention are likely to be the most effective means for reducing morbidity and mortality of human cancer. However, development of methods for noninvasive detection of early-stage tumors has remained a challenge. We have developed an approach called targeted error correction sequencing (TEC-Seq) that allows ultrasensitive direct evaluation of sequence changes in circulating cell-free DNA using massively parallel sequencing. We have used this approach to examine 58 cancer-related genes encompassing 81 kb. Analysis of plasma from 44 healthy individuals identified genomic changes related to clonal hematopoiesis in 16% of asymptomatic individuals but no alterations in driver genes related to solid cancers. Evaluation of 200 patients with colorectal, breast, lung, or ovarian cancer detected somatic mutations in the plasma of 71, 59, 59, and 68%, respectively, of patients with stage I or II disease. Analyses of mutations in the circulation revealed high concordance with alterations in the tumors of these patients. In patients with resectable colorectal cancers, higher amounts of preoperative circulating tumor DNA were associated with disease recurrence and decreased overall survival. These analyses provide a broadly applicable approach for noninvasive detection of early-stage tumors that may be useful for screening and management of patients with cancer.

Forfattere: Phallen J, Sausen M, Adleff V, Leal A, Hruban C, White J, Anagnostou V, Fiksel J, Cristiano S, Papp E, Speir S, Reinert T, Orntoft MW, Woodward BD, Murphy D, Parpart-Li S, Riley D, Nesselbush M, Sengamalay N, Georgiadis A, Li QK, Madsen MR, Mortensen FV, Huiskens J, Punt C, van Grieken N, Fijneman R, Meijer G, Husain H, Scharpf RB, Diaz LA, Jones S, Angiuoli S, Ørntoft T, Nielsen HJ, Andersen CL, Velculescu VE

Se på Pub MED

Discovery and validation of a colorectal cancer classifier in a new blood test with improved performance for high-risk subjects.

Clinical proteomics (2017 ) p. 28 issn:1542-6416) The aim was to improve upon an existing blood-based colorectal cancer (CRC) test directed to high-risk symptomatic patients, by developing a new CRC classifier to be used with a new test embodiment. The new test uses a robust assay format-electrochemiluminescence immunoassays-to quantify protein concentrations. The aim was achieved… Continue Reading

Clinical implications of monitoring circulating tumor DNA in patients with colorectal cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research (2017 Jun) issn:1078-0432) We investigated if detection of circulating tumor DNA (ctDNA) after resection of colorectal cancer (CRC) identifies the patients with the highest risk of relapse, and furthermore, whether longitudinal ctDNA analysis allows early detection of relapse and informs about… Continue Reading

Serological biomarkers in triage of FIT-positive subjects?

Scandinavian journal of gastroenterology (2017 Mar) p. 1-3 issn:1502-7708) FIT-based colorectal cancer screening has been implemented in many countries including Denmark, where 916 colorectal cancer and 4468 high- or medium-risk adenoma patients were identified within April-December 2014, among 16,806 subjects with a positive FIT test. Screening increases the overall requirements for colonoscopy, which may challenge… Continue Reading

Detection of colorectal neoplasia: Combination of eight blood-based, cancer-associated protein biomarkers.

International journal of cancer (2016 Dec) issn:1097-0215) Serological biomarkers may be an option for early detection of colorectal cancer (CRC). The present study assessed 8 cancer-associated protein biomarkers in plasma from subjects undergoing first time ever colonoscopy due to symptoms attributable to colorectal neoplasia. Plasma AFP, CA19-9, CEA, hs-CRP, CyFra21-1, Ferritin, Galectin-3, and TIMP-1 were… Continue Reading

Pre-analytical variables of circulating cell-free nucleosomes containing 5-methylcytosine DNA or histone modification H3K9Me3.

Scandinavian journal of clinical and laboratory investigation (2016 Oct) Issue 6 p. 448-53 issn:1502-7686) To evaluate pre-analytical variables of circulating cell-free nucleosomes containing 5-methylcytosine DNA (5mC) or histone modification H3K9Me3 (H3K9Me3). Forfattere: Rasmussen L, Herzog M, Rømer E, Micallef J, Bulut O, Wilhelmsen M, Christensen IJ, Nielsen HJ Se på Pub MED Continue Reading

Protocol Outlines for Parts 1 and 2 of the Prospective Endoscopy III Study for the Early Detection of Colorectal Cancer: Validation of a Concept Based on Blood Biomarkers.

JMIR research protocols (2016 ) Issue 3 p. e182 issn:1929-0748) Programs for population screening of colorectal cancer (CRC) have been implemented in several countries with fecal immunochemical testing (FIT) as the preferred platform. However, the major obstacle for a feces-based testing method is the limited compliance that reduces the clinical sensitivity for detection of participants… Continue Reading

miRNA profiling of circulating EpCAM(+) extracellular vesicles: promising biomarkers of colorectal cancer.

Journal of extracellular vesicles (2016 ) p. 31488 Cancer cells secrete small membranous extracellular vesicles (EVs) into their microenvironment and circulation. These contain biomolecules, including proteins and microRNAs (miRNAs). Both circulating EVs and miRNAs have received much attention as biomarker candidates for non-invasive diagnostics. Here we describe a sensitive analytical method for isolation and subsequent… Continue Reading

Localization of active, dually phosphorylated extracellular signal-regulated kinase 1 and 2 in colorectal cancer with or without activating BRAF and KRAS mutations.

Human pathology (2016 Aug) p. 37-46 issn:1532-8392) Colorectal cancers (CRC) often show activating mutations of the KRAS or BRAF genes, which stimulate the extracellular signal-regulated kinase (ERK) pathway, thus increasing cell proliferation and inhibiting apoptosis. However, immunohistochemical results on ERK activation in such tumors differ greatly. Recently, using a highly optimized immunohistochemical method, we obtained… Continue Reading

TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: A potential novel approach to the treatment of metastatic colorectal cancer.

Oncotarget (2016 Aug) issn:1949-2553) It is now widely accepted that therapeutic antibodies targeting epidermal growth factor receptor (EGFR) can have efficacy in KRAS wild-type advanced colorectal cancer (CRC) patients. What remains to be ascertained is whether a subgroup of KRAS-mutated CRC patients might not also derive benefit from EGFR inhibitors. Metalloproteinase inhibitor 1 (TIMP-1) is… Continue Reading

Increased serological cancer-associated biomarker levels at large bowel endoscopy and risk of subsequent primary cancer (†).

Scandinavian journal of gastroenterology (2016 Jul) Issue 7 p. 860-5 issn:1502-7708) Frequently, subjects offered colonoscopy due to symptoms of colorectal neoplasia are diagnosed with diverticula. The symptoms may, however, also be related to extra-colonic neoplasia. The present retrospective study evaluated a possible association between increased levels of predefined biomarkers in subjects diagnosed with diverticula and… Continue Reading

Plasma levels of OLFM4 in normals and patients with gastrointestinal cancer.

Journal of cellular and molecular medicine (2015 Dec) Issue 12 p. 2865-73 issn:1582-4934) Olfactomedin 4 (OLFM4) is a secreted glycoprotein predominantly expressed in bone marrow and gastrointestinal tissues. Aberrant expression of OLFM4 has been shown in several cancers. However, the clinical significance hereof is currently controversial. OLFM4 has been proposed as a candidate biomarker of… Continue Reading

The prognostic and predictive value of soluble of type IV collagen in colorectal cancer: A retrospective multicenter study.

Clinical cancer research : an official journal of the American Association for Cancer Research (2015 Dec) issn:1078-0432) To investigate the prognostic and predictive biomarker value of type IV collagen in colorectal cancer (CRC). Forfattere: Rolff HC, Christensen IJ, Vainer B, Svendsen LB, Loevendahl Eefsen R, Wilhelmsen M, Lund IK, Hoyer-Hansen G, Nielsen HJ, Illemann M… Continue Reading

Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab.

International journal of cancer. Journal international du cancer (2015 Feb) (issn:1097-0215) Circulating forms of the urokinase plasminogen activator receptor (uPAR) are associated with prognosis in patients with colorectal cancer. Preclinical studies have shown that uPAR can influence the state of phosphorylation and signalling activity of the epidermal growth factor receptor (EGFR) in a ligand-independent manner.… Continue Reading

Performance of the colorectal cancer screening marker Sept9 is influenced by age, diabetes and arthritis: a nested case-control study.

BMC cancer (2015 Oct) p. 819 issn:1471-2407) Annually, colorectal cancer (CRC) is diagnosed in >1.4 million subjects worldwide and incidence is increasing. Much effort has therefore been focused on screening, which has proven to reduce cancer-related mortality. The Sept9 DNA-methylation assay is among the most well studied blood-based screening markers. However, earlier reported performances may… Continue Reading

Phospho-ERK1/2 levels in cancer cell nuclei predict responsiveness to radiochemotherapy of rectal adenocarcinoma.

Oncotarget (2015 Oct) Issue 33 p. 34321-8 issn:1949-2553) Locally advanced rectal adenocarcinoma is treated with radiochemotherapy (RCT) before surgery. The response to RCT is heterogeneous and consensus regarding reliable predictors is lacking. Since the ERK pathway is implicated in radioprotection, we examined pretreatment biopsies from 52 patients by immunohistochemistry for phosphorylated ERK (pERK). Immunostaining for… Continue Reading

Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer.

Gut (2015 Sep) issn:1468-3288) To evaluate the potential for diagnosing colorectal cancer (CRC) from faecal metagenomes. Forfattere: Yu J, Feng Q, Wong SH, Zhang D, Liang QY, Qin Y, Tang L, Zhao H, Stenvang J, Li Y, Wang X, Xu X, Chen N, Wu WK, Al-Aama J, Nielsen HJ, Kiilerich P, Jensen BA, Yau TO,… Continue Reading

TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine (2015 Jan) (issn:1423-0380) KRAS wild-type (wt) status determines indication for treatment with combination therapy, including epidermal growth factor receptor (EGFR) inhibitors, but still, the overall response rate in KRAS wt patients is less than 40 %. Consequently, the majority of patients will… Continue Reading

Topoisomerase-1 and -2A gene copy numbers are elevated in mismatch repair-proficient colorectal cancers.

Molecular oncology (2015 Mar) (issn:1878-0261) Topoisomerase 1 (TOP1) and 2A (TOP2A) are potential predictive biomarkers for irinotecan and anthracycline treatment, respectively, in colorectal cancer (CRC), and we have recently reported a high frequency of gene gain of  the TOP1 and TOP2A genes in CRC. Furthermore, Mismatch Repair (MMR) subtypes of CRC have been associated with… Continue Reading

Serum YKL-40 in Risk Assessment for Colorectal Cancer: A Prospective Study of 4,496 Subjects at Risk of Colorectal Cancer.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2015 Mar) issue 3 p. 621-6 (issn:1538-7755) The aim of the present study was to test the hypothesis that high serum YKL-40 associates with colorectal cancer in subjects at risk of colorectal… Continue Reading

Microbiota disbiosis is associated with colorectal cancer.

Frontiers in microbiology (2015 ) p. 20 issn:1664-302X) The dysbiosis of the human intestinal microbiota is linked to sporadic colorectal carcinoma (CRC). The present study was designed to investigate the gut microbiota distribution features in CRC patients. We performed pyrosequencing based analysis of the 16S rRNA gene V3 region to investigate microbiota of the cancerous… Continue Reading

Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery.

Gut (2015 Feb) issn:1468-3288) To develop an affordable and robust pipeline for selection of patient-specific somatic structural variants (SSVs) being informative about radicality of the primary resection, response to adjuvant therapy, incipient recurrence and response to treatment performed in relation to diagnosis of recurrence. Forfattere: Reinert T, Schøler LV, Thomsen R, Tobiasen H, Vang S,… Continue Reading

IQGAP1 in rectal adenocarcinomas: localization and protein expression before and after radiochemotherapy.

Cancer letters (2015 Jan) issue 2 Pt B p. 556-60 (issn:1872-7980) Treatment of rectal adenocarcinoma includes total mesorectal excision, which is preceded by radiochemotherapy (RCT) in cases of advanced disease. The response to RCT varies from total tumor regression to no effect but this heterogeneous response is unexplained. However, both radiation and treatment with 5-fluorouracil… Continue Reading

Evaluation of complement proteins as screening markers for colorectal cancer.

Cancer immunology, immunotherapy : CII (2015 Jan) Issue 1 p. 41-50 issn:1432-0851) Colorectal cancer (CRC) is a leading cause of cancer death worldwide. Lack of symptoms results in late detection and increased mortality. Inflammation, including complement activation, plays an important role in tumorigenesis. Forfattere: Storm L, Christensen IJ, Jensenius JC, Nielsen HJ, Thiel S, Se… Continue Reading

Circulating intact and cleaved forms of the urokinase-type plasminogen activator receptor: biological variation, reference intervals and clinical useful cut-points.

Clinica chimica acta; international journal of clinical chemistry (2015 Jan) p. 84-90 issn:1873-3492) High levels of circulating forms of the urokinase-type plasminogen activator receptor (uPAR) are significantly associated to poor prognosis in cancer patients. Our aim was to determine biological variations and reference intervals of the uPAR forms in blood, and in addition, to test… Continue Reading

Determinants of recurrence after intended curative resection for colorectal cancer.

Scandinavian journal of gastroenterology (2014 Dec) Issue 12 p. 1399-408 issn:1502-7708) Despite intended curative resection, colorectal cancer will recur in ?45% of the patients. Results of meta-analyses conclude that frequent follow-up does not lead to early detection of recurrence, but improves overall survival. The present literature shows that several factors play important roles in development… Continue Reading

Positron emission tomography/computed tomography for optimized colon cancer staging and follow up.

Scandinavian journal of gastroenterology (2014 Feb) Issue 2 p. 191-201 issn:1502-7708) Optimal management of colon cancer (CC) requires detailed assessment of extent of disease. This study prospectively investigates the diagnostic accuracy of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography (PET/CT) for staging and detection of recurrence in primary CC. Forfattere: Engelmann BE, Loft A, Kjær A, Nielsen… Continue Reading

COL6A3 expression in adipocytes associates with insulin resistance and depends on PPAR? and adipocyte size.

Obesity (Silver Spring, Md.) (2014 Aug) issue 8 p. 1807-13 (issn:1930-739X) COL6A3 may modulate adipose tissue function in obesity and insulin resistance. A role for human adipocytes linking COL6A3 with insulin resistance warrants exploration. Forfattere: Dankel SN, Svärd J, Matthä S, Claussnitzer M, Klöting N, Glunk V, Fandalyuk Z, Grytten E, Solsvik MH, Nielsen HJ,… Continue Reading

Urokinase-type plasminogen activator receptor (uPAR) on tumor-associated macrophages is a marker of poor prognosis in colorectal cancer.

Cancer medicine (2014 Aug) Issue 4 p. 855-64 issn:2045-7634) Patients were identified from a population-based prospective study of 4990 individuals with symptoms associated with colorectal cancer (CRC). A total of 244 CRC tissue samples were available for immunohistochemical staining of uPAR, semiquantitatively scored at the invasive front, and in the tumor core on cancer cells,… Continue Reading

Prognostic and predictive value of cathepsin X in serum from colorectal cancer patients.

BMC cancer (2014 ) p. 259 issn:1471-2407) Cathepsin X is a cysteine protease involved in mechanisms of malignant progression. It is secreted from tumour cells as a proenzyme and may serve to predict the disease status and risk of death for cancer patients. In a previous, pilot, study on 77 colorectal patients we demonstrated the… Continue Reading

[Screening methods for colorectal cancer can be improved.]

Ugeskrift for laeger (2014 Mar) Issue 11B issn:1603-6824) Screening programmes for colorectal cancer (CRC) are being implemented in various countries worldwide including Denmark. The majority of programmes rely on faecal occult blood testing with subsequent colonoscopy. This approach is challenged by limited compliance, which reduces the efficiency of the screening programme. Current research into improve-ments… Continue Reading

Measuring ERCC1 protein expression in cancer specimens: validation of a novel antibody.

Scientific reports (2014 ) p. 4313 issn:2045-2322) Platinum chemotherapy remains part of standard therapies in the management of a variety of cancers. Severe side effects and a high degree of resistance to platinum drugs have led numerous researchers to search for predictive biomarkers, which could aid in identifying patients that are the most likely to… Continue Reading

Positron emission tomography/computed tomography and biomarkers for early treatment response evaluation in metastatic colon cancer.

The oncologist (2014 Feb) Issue 2 p. 164-72 issn:1549-490X) Treatment options for metastatic colon cancer (mCC) are widening. We prospectively evaluated serial 2-deoxy-2-[18F]fluoro-d-glucose positron-emission tomography/computed tomography (PET/CT) and measurements of tissue inhibitor of metalloproteinases-1 (TIMP-1), carcinoembryonic antigen (CEA), and liberated domain I of urokinase plasminogen activator receptor (uPAR(I)) for early assessment of treatment response in… Continue Reading

Assessment of the topoisomerase I gene copy number as a predictive biomarker of objective response to irinotecan in metastatic colorectal cancer.

Scandinavian journal of gastroenterology (2014 Jan) issue 1 p. 84-91 (issn:1502-7708) DNA topoisomerase I is a putative biomarker of irinotecan efficacy with clinical associations previously demonstrated at the protein level. The purpose of the present study was to perform the first clinical investigation of the association between the DNA topoisomerase I gene (TOP1) copy number… Continue Reading

Underpinning the repurposing of anthracyclines towards colorectal cancer: assessment of topoisomerase II alpha gene copy number alterations in colorectal cancer.

Scandinavian journal of gastroenterology (2013 Dec) Issue 12 p. 1436-43 issn:1502-7708) OBJECTIVE. We propose a repurposing strategy where anthracyclines are reintroduced to a subgroup of patients with metastatic colorectal cancer with the highest likelihood of response. In breast cancer, DNA topoisomerase II alpha gene (TOP2A) alterations predict incremental benefit of anthracyclines, but this association has… Continue Reading

An explorative analysis of ERCC1-19q13 copy number aberrations in a chemonaive stage III colorectal cancer cohort.

BMC cancer (2013 ) p. 489 issn:1471-2407) Platinum-based chemotherapy has long been used in the treatment of a variety of cancers and functions by inducing DNA damage. ERCC1 and ERCC4 are involved in the removal of this damage and have previously been implicated in resistance to platinum compounds. The aim of the current investigation is… Continue Reading

Detection of serological biomarkers by proximity extension assay for detection of colorectal neoplasias in symptomatic individuals.

Journal of translational medicine (2013 ) p. 253 issn:1479-5876) Although the potential of biomarkers to aid in early detection of colorectal cancer (CRC) is recognized and numerous biomarker candidates have been reported in the literature, to date only few molecular markers have been approved for daily clinical use. Forfattere: Thorsen SB, Lundberg M, Villablanca A,… Continue Reading

Polymorphisms in the MASP1 gene are associated with serum levels of MASP-1, MASP-3, and MAp44.

PloS one (2013 ) Issue 9 p. e73317 issn:1932-6203) MASP-1 is the first protein in the activation of the lectin pathway and MASP-1 is, like its isoforms MASP-3 and MAp44, encoded by the MASP1 gene. Our aim was to explore associations between polymorphisms in MASP1 and corresponding concentrations of MASP-1, MASP-3, and MAp44 in plasma… Continue Reading

Investigations on collectin liver 1.

The Journal of biological chemistry (2013 Aug) Issue 32 p. 23407-20 issn:1083-351X) Collectins are pattern recognition molecules of the innate immune system showing binding to carbohydrate structures on microorganisms in a calcium-dependent manner. Recently, three novel collectins, collectin liver 1 (CL-L1), collectin kidney 1 (CL-K1 and CL-11), and collectin placenta 1 (CL-P1), were discovered. The… Continue Reading

Tissue inhibitor of metalloproteinases-1 as a biological marker in colorectal cancer: influence of smoking on plasma levels?

The International journal of biological markers ( ) Issue 2 p. 226-30 issn:1724-6008) At present plasma tissue inhibitor of metalloproteinases-1 (TIMP-1) is undergoing validation as a biological marker in colorectal cancer (CRC). The clinical implementation of plasma TIMP-1 in prognosis, prediction, screening and monitoring CRC requires robust information as to the influence of preanalytical factors,… Continue Reading

Mechanisms of topoisomerase I (TOP1) gene copy number increase in a stage III colorectal cancer patient cohort.

PloS one (2013 ) Issue 4 p. e60613 issn:1932-6203) Topoisomerase I (Top1) is the target of Top1 inhibitor chemotherapy. The TOP1 gene, located at 20q12-q13.1, is frequently detected at elevated copy numbers in colorectal cancer (CRC). The present study explores the mechanism, frequency and prognostic impact of TOP1 gene aberrations in stage III CRC and… Continue Reading

Early detection of recurrence after curative resection for colorectal cancer – obstacles when using soluble biomarkers?

Scandinavian journal of gastroenterology (2013 Mar) Issue 3 p. 326-33 issn:1502-7708) Results from monitoring studies using biomarkers in blood samples aiming at early detection of recurrent colorectal cancer (CRC) are presently evaluated. However, some serological biomarker levels are influenced by the surgical trauma, which may complicate translation of the levels in relation to recurrence. The… Continue Reading

Data fusion in metabolomic cancer diagnostics.

Metabolomics : Official journal of the Metabolomic Society (2013 Feb) Issue 1 p. 3-8 issn:1573-3882) We have recently shown that fluorescence spectroscopy of plasma samples has promising abilities regarding early detection of colorectal cancer. In the present paper, these results were further developed by combining fluorescence with the biomarkers, CEA and TIMP-1 and traditional metabolomic… Continue Reading

Topoisomerase 1(TOP1) gene copy number in stage III colorectal cancer patients and its relation to prognosis.

Molecular oncology (2013 Feb) Issue 1 p. 101-11 issn:1878-0261) A Topoisomerase 1 (Top1) poison is frequently included in the treatment regimens for metastatic colorectal cancer (mCRC). However, no predictive biomarkers for Top1 poisons are available. We here report a study on the TOP1 gene copy number in CRC patients and its association with patient prognosis… Continue Reading

Non-synonymous polymorphisms in the FCN1 gene determine ligand-binding ability and serum levels of M-ficolin.

PloS one (2012 ) Issue 11 p. e50585 issn:1932-6203) The innate immune system encompasses various recognition molecules able to sense both exogenous and endogenous danger signals arising from pathogens or damaged host cells. One such pattern-recognition molecule is M-ficolin, which is capable of activating the complement system through the lectin pathway. The lectin pathway is… Continue Reading

Saliva and plasma TIMP-1 in patients with colorectal cancer: a prospective study.

Scandinavian journal of gastroenterology (2012 Oct) Issue 10 p. 1234-41 issn:1502-7708) A prospective cross-sectional study was designed to test if total levels of TIMP-1 in saliva and plasma correlated with the diagnosis of colorectal cancer (CRC) in a population with symptoms consistent with this disease. Forfattere: Holten-Andersen L, Christensen IJ, Jensen SB, Reibel J, Laurberg… Continue Reading

Cathepsin X in serum from patients with colorectal cancer: relation to prognosis.

Radiology and oncology (2012 Sep) Issue 3 p. 207-12 issn:1581-3207) Up-regulation of lysosomal cysteine protease cathepsin X (Cat X) is associated with disorders of the immune system and neurodegenerative diseases, while its role in the development and progression of cancer is less understood. Enhanced secretion of pro-Cat X was observed in malignant processes, and therefore,… Continue Reading

Screening for colorectal cancer: possible improvements by risk assessment evaluation?

Scandinavian journal of gastroenterology (2011 Nov) Issue 11 p. 1283-94 issn:1502-7708) Emerging results indicate that screening improves survival of patients with colorectal cancer. Therefore, screening programs are already implemented or are being considered for implementation in Asia, Europe and North America. At present, a great variety of screening methods are available including colono- and sigmoidoscopy,… Continue Reading

Plasma TIMP-1 and CEA in detection of primary colorectal cancer: a prospective, population based study of 4509 high-risk individuals.

Scandinavian journal of gastroenterology (2011 Jan) Issue 1 p. 60-9 issn:1502-7708) The combination of plasma tissue inhibitor of metalloproteinases-1 (TIMP-1) and carcinoembryonic antigen (CEA) may be valuable biomarkers for early detection of colorectal cancer (CRC). A prospective, population based study was performed to validate this hypothesis. Forfattere: Nielsen HJ, Brünner N, Jorgensen LN, Olsen J,… Continue Reading

Plasma TIMP-1 and CEA as Markers for Detection of Primary Colorectal Cancer: A Prospective Validation Study Including Symptomatic and Non-symptomatic Individuals.

Anticancer research (2015 Sep) Issue 9 p. 4935-41 issn:1791-7530) The combination of plasma tissue inhibitor of metalloproteinases-1 (1) and CEA has been shown to have utility in early detection of colorectal cancer (2). A prospective study was performed to validate previous findings. Forfattere: Christensen IJ, Brünner N, Dowell B, Davis G, Nielsen HJ, Newstead G,… Continue Reading

Intact and cleaved forms of the urokinase receptor enhance discrimination of cancer from non-malignant conditions in patients presenting with symptoms related to colorectal cancer.

British journal of cancer (2009 Sep) Issue 6 p. 992-7 issn:1532-1827) Colorectal cancer (CRC) is a leading cause of cancer-related morbidity and mortality in developed countries. It is known that early detection results in improved survival, and consequently there is a need for improved diagnostic tools in CRC. The plasma level of soluble urokinase plasminogen… Continue Reading

Banking of biological fluids for studies of disease-associated protein biomarkers.

Molecular & cellular proteomics : MCP (2008 Oct) Issue 10 p. 2061-6 issn:1535-9484) With the increasing demand of providing personalized medicine the need for biobanking of biological material from individual patients has increased. Such samples are essential for molecular research aimed at characterizing diseases at several levels ranging from epidemiology and diagnostic and prognostic classification… Continue Reading

Haemostatic alterations in colorectal cancer: perspectives for future treatment.

Journal of surgical oncology (2004 Dec) Issue 4 p. 269-75 issn:0022-4790) The role of the haemostatic system in colorectal cancer (CRC) is reviewed. Correlations between the activation of the haemostatic system and overall survival have been suggested. Experimental studies indicate that the haemostatic system plays a key role in growth, invasion and dissemination of tumour… Continue Reading

Donation / Partnerskab

Er du interesseret i at donere til vores forskning som privatperson, virksomhed eller forening?

Dit navn *

Din e-mail *

Dit tlf. nummer

Din besked *

  Emne

Kontaktoplysninger

ColoRectal Cancer Research

Gastroenheden, Hvidovre Hospital

Kettegård Allé 30

2650 Hvidovre

Email: info@colorectalcancer.dk